Today: 9 April 2026
Rocket Lab stock jumps, then insider sale plan emerges — what to know before Monday
4 January 2026
2 mins read

Rocket Lab stock jumps, then insider sale plan emerges — what to know before Monday

NEW YORK, Jan 4, 2026, 5:35 PM ET — Market closed

  • Rocket Lab shares surged 8.9% on Friday, ending at $75.99.
  • A late-day SEC Form 144 showed COO Frank Klein plans to sell up to 100,000 shares under a 10b5-1 plan.
  • Focus turns to timing of Neutron milestones and the company’s next earnings update.

Rocket Lab Corp shares closed up 8.9% on Friday at $75.99, even as a regulatory filing showed the company’s chief operating officer has lined up a potential sale of stock. Yahoo Finance

The filing matters because Rocket Lab’s rally has pushed the stock toward its recent highs, leaving traders sensitive to any sign insiders are cashing out. A Form 144 is a required notice when an insider intends to sell restricted or control securities, and it can draw scrutiny even when it is procedural. SEC

Klein’s notice also referenced a Rule 10b5-1 plan, a pre-arranged trading program that can allow executives to sell shares on a set schedule and help reduce the perception they are trading on nonpublic information. SEC

The Form 144 filed on Jan. 2 listed up to 100,000 Rocket Lab common shares with an aggregate market value of about $6.98 million and named Morgan Stanley Smith Barney as the broker. The filing said the shares to be sold were acquired through the vesting of restricted stock units, and it was signed by Klein. SEC

Rocket Lab traded between $66.85 and $76.24 on Friday after opening at $70.63, according to historical pricing data. The stock’s move came on volume of about 31.4 million shares. Yahoo Finance

Some investors have tied the broader bid for space and defense-linked names to Rocket Lab’s expanding role in U.S. national security satellite work. In December, the U.S. Space Development Agency placed a $3.5 billion order for 72 satellites, and Reuters reported Rocket Lab was among the companies signing fixed-price contracts for 18 space vehicles each. Reuters

Rocket Lab’s operational tempo has also been a talking point. In a Jan. 2 PRNewswire release, CEO Sir Peter Beck said the company planned to broaden Electron’s cadence and reach this year, pointing to “more multi-launch constellation deployments” and missions tied to civil and defense demand. PR Newswire

Analyst chatter has stayed active after the run. MarketBeat reported that research platform Wall Street Zen lifted its Rocket Lab rating to “hold” from “sell,” while also listing the stock’s 12-month high near $79.83 and a 50-day moving average around $56—one common gauge traders use to judge trend strength. MarketBeat

A key risk is that the stock’s momentum fades as investors reassess valuation against execution, especially with Rocket Lab still loss-making. In its most recent quarterly update, Rocket Lab posted record revenue of $155.08 million and guided for fourth-quarter 2025 revenue of $170 million to $180 million. Rocket Lab Investors

Next up is the company’s next earnings release and any refreshed timeline on larger-rocket milestones. Nasdaq’s calendar currently estimates Rocket Lab will report results on Feb. 26, though the company has not confirmed a date, and other tracking services show a late-February window. Nasdaq

Stock Market Today

  • Guard Therapeutics Faces Potential Delisting from Nasdaq First North Growth Market
    April 9, 2026, 12:06 PM EDT. Guard Therapeutics International AB has been notified by Nasdaq that it currently fails to meet the active operations requirement, risking delisting by June 17, 2026. The company is exploring a merger or reverse acquisition to satisfy Nasdaq's operational criteria. A transaction structure is expected to be proposed in Q2 2024, allowing Nasdaq to reassess the listing status. If no agreement is reached, the board will recommend voluntary delisting and liquidation, returning available funds to shareholders. Final decisions will be taken by shareholders at a general meeting. Guard Therapeutics focuses on developing therapies for kidney diseases based on the alpha-1-microglobulin protein and is listed under the ticker GUARD.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
JPMorgan stock holds near record highs as Wall Street braces for Jan. 13 earnings and key U.S. data
Previous Story

JPMorgan stock holds near record highs as Wall Street braces for Jan. 13 earnings and key U.S. data

SOHO spots water gushing from interstellar comet 3I/ATLAS after its Sun pass
Next Story

SOHO spots water gushing from interstellar comet 3I/ATLAS after its Sun pass

Go toTop